Addressing challenges in characterizing novel AAV capsids and gene editing platform-driven therapeutics

Abstract

<div class="authors authors-lg"><div class="author"><div class="author-img"><img src="https://bioinsights.blob.core.windows.net/uploads/Drouin_headshot copy.jpg" data-image="1"></div><div class="author-det"> <b>Lauren M Drouin</b> leads the Analytical Development group at LogicBio Therapeutics, where she supports the development and implementation of analytical methodologies needed to progress LB-001 and other pipeline products from preclinical development into the clinic and beyond. Current research interests include novel AAV capsid characterization and developing a robust understanding of the factors that influence potency of gene therapy products. Previously, Lauren worked at Voyager Therapeutics where she was responsible for analytical method development and overseeing CMC analytics operations for the Parkinson’s Disease clinical program. Lauren received her PhD in Biochemistry and Molecular Biology from the University of Florida where she utilized molecular, biophysical, and structural techniques to characterize the AAV capsid for improved gene delivery. </div></div></div>